FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay

Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet